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Abstract
Background—Nonmedical prescription opioid use has been linked to hepatitis C virus (HCV) 
infection among people who inject drugs and with using high dead space syringes that retain more 
blood and transfer more HIV if shared. Little is known regarding its effects on sex risk behaviors.
Objectives—This paper examines event-level associations between nonmedical prescription 
opioid use and sharing high dead space syringes (injection risk) and unprotected intercourse (sex 
risk) behaviors.
Methods—We recruited 1,985 participants from two overlapping risk groups--drug users and 
men who have sex with men (MSM)—and their sex partners. Participants completed an interview 
that included event-level sex questions with recent sex partners and injection questions with recent 
injection partners. We used multivariable generalized estimating equations (GEE) to assess the 
associations between nonmedical prescription opioid use and unprotected intercourse during 
sexual encounters and sharing syringes during injection episodes, while adjusting for within-
person correlations.
Results—When both partners used nonmedical prescription opioids, its use was independently 
associated with unprotected intercourse in sexual encounters (OR = 2.24; 95% CI = 1.12, 4.49). 
The use of nonmedical prescription opioids was also associated with sharing high dead space 
syringes during injection episodes (OR = 6.57; 95% CI = 1.63, 26.51).
Conclusion—Nonmedical prescription opioid use is associated with an increase in the risk of 
unprotected sex and sharing high dead space syringes. HIV and HCV prevention interventions for 
nonmedical prescription opioid users should address sex risk behaviors and encourage the use of 
acceptable low dead space needles and syringes.
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27709-2194, zule@rti.org. 
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Introduction
Nonmedical use of prescription opioids has received considerable attention in recent years 
(1). It has been associated with an increased risk of hepatitis C virus (HCV) infection among 
people who inject drugs (PWID) (2, 3). It is also an important driver of the increase in 
deaths due to accidental opioid overdose (4, 5). Nonmedical use of prescription opioids is 
common in both rural and urban areas (1, 6). Recent changes in prescribing practices (7) 
now make it more difficult to obtain prescription opioids, but these prescribing practices 
have yielded the unintended consequence of shifting some nonmedical prescription opioid 
users to heroin (8).
Despite the growing body of research related to the dangers of nonmedical prescription 
opioid use, the association between nonmedical prescription opioid use and sex risk 
behaviors has received little attention. Although an association between nonmedical 
prescription opioid use and sex risk behaviors has been noted among men who have sex with 
men (MSM) (9, 10), there are few reports of its effects among heterosexuals. One study 
identified an association between concurrent heavy alcohol and cocaine use and reporting 
multiple sexual partners in the last month among nonmedical prescription opioid users 
entering substance use disorder treatment, 97% of whom reported opposite sex partners (11). 
In the same study, a history of dependence on a substance other than prescription opioids 
was associated with unprotected intercourse in the last month. In a qualitative study of 46 
nonmedical prescription opioid users in New York City, a number of participants reported 
engaging in unprotected intercourse while using prescription opioids (12).
The associations between drug use and sexual behavior vary by drug (13) and by 
characteristics of the sexual encounter (14, 15). Event-level analyses of sexual encounters 
are required to disentangle the effects of specific drugs (e.g., alcohol, methamphetamine, 
prescription opioids), characteristics of individuals (e.g., age, race/ethnicity, education level), 
partner characteristics (e.g., main, casual, transactional), and situational factors (e.g., 
discordant HIV status, drug use by partner) (16, 17). In this sample, we hypothesized that 
non-medical prescription opioid use would be associated with unprotected intercourse in 
event-level analyses.
In contrast with sex risk, about which little is known, evidence suggests that nonmedical 
prescription opioid use may be associated with increased injection risk. Specifically, 
nonmedical prescription opioid injection has been identified as an independent risk factor for 
HCV infection compared with injecting heroin or other drugs in models that adjusted for 
unsafe injecting practices (18). The specific reasons for this association are not completely 
clear. However, several reports have noted that nonmedical prescription opioid users often 
inject volumes of fluid greater than 1-ml (18, 19), which is the maximum volume of most 
“low dead space” insulin syringes (20, 21). As a consequence, nonmedical prescription 
opioid users may be more likely to use standard “high dead space” needles and syringes. 
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Compared with insulin syringes, these syringes retain larger volumes of blood (22) and may 
transmit higher numbers of HCV viral particles if shared (23). Evidence suggests that 
exposures involving high dead space needles and syringes carry a greater risk of HIV and 
HCV transmission than exposures involving low dead space syringes (23–25). The World 
Health Organization (WHO) recommends low dead syringes as one option for reducing 
injection-related HCV transmission among PWID (26). To our knowledge, the relationship 
between nonmedical prescription opioid injection and the use of high dead space syringes 
has not been assessed in statistical models. Moreover, we are not aware of any published 
studies that have examined the correlates of high dead space syringe sharing at the level of 
the injection episode.
We hypothesized that injecting nonmedical prescription opioids would be associated with 
using and sharing a high dead space syringe. We also hypothesized that using a common 
syringe to prepare and divide liquefied drug solution would be associated with using and 
sharing a high dead space syringe. This is because the volume of liquid tends to exceed 1 ml 
when drugs are prepared for more than one person leading PWID to use larger (high dead 
space) syringes. Moreover, some PWID prefer to transfer the drug solution directly from one 
syringe to the other through practices that researchers refer to as “frontloading” and 
“backloading” (27, 28). Directly transferring liquefied drugs from one syringe to another 
using a low dead space insulin syringe with a permanently attached needle requires 
“backloading” (29), which carries a high risk of spilling drugs (27). In contrast, there is 
little, if any, risk of spilling drugs during “frontloading” (30), which requires a syringe with 
a detachable needle, which in the US context means a high dead space syringe.
This study analyzed data from 1,985 respondents in a cross-sectional study conducted in two 
rural and two urban counties in North Carolina. We begin by comparing the demographic, 
drug use, risk behavior, and other characteristics of participants who reported using 
nonmedical prescription opioids in the past 30 days with participants who did not report 
using them. We then examine the associations between nonmedical prescription opioid use 
and unprotected sex (i.e., vaginal or anal intercourse without using a condom during a sexual 
encounter) through event-level analyses. Next, we use event-level analyses of injection 
episodes to examine the association between injecting prescription opioids, the use of a 
common syringe to prepare and divide drugs (i.e. syringe-mediated drug sharing), and 
sharing a high dead space syringe.
Methods
Event-level analyses were undertaken to assess associations between nonmedical 
prescription opioid use and HIV risk behaviors (i.e. unprotected sex and sharing high dead 
space syringes). Compared with analyses of global associations or of situational 
associations, analyses of event-level associations provide a more sensitive and rigorous 
method for assessing relationships between use of a substance and sex risk or injection risk 
behaviors (31).
The data were collected as part of the North Carolina (NC) site of the Sexual Acquisition 
and Transmission of HIV Cooperative Agreement Project (SATHCAP), which was funded 
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by the National Institute on Drug Abuse (32). The methods of the overall SATHCAP and the 
NC SATHCAP have been described previously (33, 34). All of the SATHCAP sites used 
respondent driven sampling (RDS) to recruit participants (33, 35).
The purpose of the SATHCAP was to explore the potential for sexual diffusion of HIV from 
traditional higher risk groups (i.e. men who have sex with men and people who use drugs) to 
lower risk groups (e.g. women and non-drug users). The SATHCAP used respondent driven 
sampling (RDS), a coupon-based chain-referral approach (33, 35), to recruit participants. 
Participants recruited as MSM or people who use drugs were given RDS coupons to recruit 
other people who met the eligibility criteria as a drug user or as an MSM. In addition, the 
SATHCAP allowed participants recruited as drug users to recruit their non-drug using sex 
partners; participants who were recruited as MSM were allowed to recruit their female sex 
partners. Participants recruited as a sex partner of a drug user or a sex partner of an MSM 
could also recruit their sex partners, but these partners could not recruit anyone. The 
SATHCAP used color-coded RDS coupons to help staff distinguish between participants 
recruited as “core group members” (i.e. drug users and MSM), sex partners, and sex partners 
of sex partners. The specific eligibility criteria for each category follow:
• Participants in the SATHCAP recruited as drug users had to present a valid 
“core” coupon and report use of heroin, cocaine (powder or crack), 
methamphetamine, or injected drug use in the past 6 months;
• Male participants in the SATHCAP recruited as MSM had to report male-to-male 
anal intercourse in the past year, but they did not have to report using any drugs;
• Participants in the SATHCAP recruited as sex partners (or partners of partners) 
had to present a valid “sex partner” coupon that they had received from a study 
participant and report having sex with the person who gave them the coupon. 
They did not have to report using any drugs.
All study participants were required to be at least 18 years of age and to provide written 
informed consent.
The sample size at each site, which was agreed upon by all of the SATHCAP sites, was 
designed to provide a sample large enough to answer the primary site-specific and cross-site 
research questions. Specifically, a large sample as the one analyzed would provide power 
over 85% to detect small differences of 0.2 of the outcome’s (i.e. primary research 
questions) standard deviation. Post-hoc power analyses for the secondary outcomes 
examined in this manuscript indicated that we had over 90% power to detect associations 
that were significant at p< 0.001 and less than 50% power to detect associations that were 
non-significant (p > 0.05). RDS efficiently recruits participants from study populations 
engaging in proscribed, stigmatizing, or illegal behaviors who are often difficult to reach 
(36, 37). Participants completed an audio computer assisted self-interview (ACASI) that 
included questions on drug use, sex risk behaviors, and injection risk overall and event-level 
questions. As described in the Measures section, the interview collected information 
regarding recent sexual encounters with the three most recent sex partners plus up to four 
special interest sex partners and injection episodes with up to three injection partners. The 
RTI International Office of Research Protection provided ethical approval for this study.
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Measures
The ACASI included sections on socio-demographics (e.g., homelessness, income, gender, 
education, and marital status). It also included questions on history of incarceration and 
substance use disorder treatment. Symptoms of depression were measured with the 
depression subscale of the Brief Symptom Inventory (BSI)-18 (38).
For sexual behavior, the ACASI assessed the number of sex partners in the past six months 
and the number of occasions of vaginal and anal intercourse during the past 30 days with 
and without a condom. It also asked detailed questions regarding the most recent sexual 
encounter with the three most recent sex partners and sex partners of special interest (e.g., a 
female partner of an MSM, a non-drug using partner of a person who used drugs, the RDS 
recruiter, and an injecting partner of a person who injects drugs). We asked about the special 
interest partners because the cooperative agreement was interested in the sexual diffusion of 
HIV from traditional risk groups (e.g. MSM and people who use drugs) to women, non-drug 
users, and the general population. Encounter-level questions included the age, race/ethnicity, 
and gender of the partner; the relationship to the partner; the type(s) (i.e., oral, vaginal, anal) 
of sex during the encounter; whether a condom was used during vaginal or anal sex; drugs 
used (if any) by the participant and partner; the specific drugs used during the encounter by 
each partner; if the encounter involved sex for money or drugs and which partner was buying 
and which partner was selling; and the perceived HIV status of the partner.
The ACASI assessed lifetime and past 30-day use and injection of methamphetamine, 
powder cocaine, crack cocaine, heroin by itself, heroin and cocaine in combination 
(speedball), and nonmedical use of prescription opioids. It also asked about any alcohol use, 
drinking five or more drinks within two hours (i.e., binge drinking), and marijuana use in the 
past 30 days.
The ACASI also included questions for PWID about the last injection episode with their 
three most recent injection partners in the past six months. We restricted the questions to the 
three most recent injection partners and sex partners (mentioned previously) to reduce recall 
errors. For each injection episode, the ACASI included questions on the characteristics of 
the injecting partner, drugs the study participant injected, if he/she engaged in receptive 
syringe sharing, distributive syringe sharing, or splitting liquefied drug solution, and if the 
injecting partner was also a sex partner. To assess whether a high dead space syringe was 
used, a question asked whether the needle could be taken off of the syringe. Low dead space 
insulin syringes in the US have permanently attached needles; thus, if a study participant 
reported that the needle could be taken off, we coded this event as using a high dead space 
syringe.
Comparison of participants who reported using nonmedical prescription opioids with 
participants who did not report using them
We used the RDS Analysis Tool (RDSAT) (www.respondentdrivensampling.org) to calculate 
RDS weights, and we ran these comparisons with and without the weights.
We used the Pearson chi-square test to assess the differences in proportions of categorical 
variables between participants who reported using nonmedical prescription opioids in the 
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previous 30 days and those who did not report using them. We used a t-test for independent 
samples to assess differences in means of interval and continuous variables between groups.
Event-level unprotected intercourse analyses
We assessed event-level associations between nonmedical prescription opioid use and 
unprotected intercourse during heterosexual encounters. We excluded encounters (n=181) in 
which both partners were male because their HIV risks differ from heterosexual encounters. 
For these analyses, we used a generalized estimating equations (GEE) approach to perform 
logistic regression analyses that adjusted for within-person correlation for participants who 
reported multiple encounters. We assessed demographic characteristics and important event-
level covariates (e.g., age and race/ethnicity of each partner, depressive symptoms, sex 
trading during encounter, and drugs used). For the GEE analyses, we specified an 
exchangeable correlation structure and logit link function. For the multivariable GEE model, 
we entered all of the variables that were significant in the univariate analyses at p < 0.20. We 
also retained the ages of both partners in the model regardless of the p-value. Prior to 
beginning the analyses, we coded each event by who used each drug (i.e., no one, male 
partner only, female partner only, or both partners) and then ran cross-tabulations on each 
drug by unprotected intercourse during the event. These analyses showed that the events in 
which both partners used drugs were the most risky, followed by events in which one partner 
used. For events where one partner used, the gender of the partner did not make a difference 
in risk. Accordingly, we analyzed event-level use of each drug as a categorical variable 
defined as: no use of the drug by either partner (reference category), drug used by one 
partner, or drug used by both partners.
High dead space syringe analyses
We conducted event-level analyses of injection episodes using a GEE approach. We began 
by conducting univariate analyses to identify variables that were associated with sharing a 
high dead space syringe. For the multivariable GEE model, we entered all of the variables 
that were significant at p < 0.20 to determine if they were independently associated with 
sharing a high dead space syringe. Individual-level independent variables included: age, 
gender, race/ethnicity, education, and recruitment from a rural area. The event-level variables 
included the specific drugs that were injected and whether the event involved syringe-
mediated drug sharing (i.e., using a syringe to divide liquefied drug solution) (27).
Results
From 2005 through 2008, the NC SATHCAP recruited 1,985 participants from two urban 
(n=1,414) and two rural counties (n=571). The sample included 393 (20%) participants 
(urban n=231; rural n=162) who reported nonmedical use of prescription opioids in the 
previous 30 days.
Differences between nonmedical prescription opioid users and other study participants
The RDS weights did not substantively alter the results; therefore, only the results of the 
unweighted analyses are reported. The characteristics of the sample by nonmedical 
prescription opioid use are shown in Table 1. Compared with participants who did not use 
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nonmedical prescription opioids, those who reported using them were more likely to be 
young, female, non-Hispanic white, and recruited from a rural area. The groups were similar 
on other socio-demographic characteristics. Approximately 41% were homeless, 34% had 
health insurance, 34% legally earned at least $500/month, and 55% had ever been 
incarcerated. Compared with participants who did not report recent nonmedical use of 
prescription opioids nonmedical prescription opioid users were less likely to currently be in 
substance use disorder treatment. Nonmedical prescription opioid users were more likely 
than non-users to report binge drinking (64% vs. 48%) and use of methamphetamine (16.3% 
vs. 2%), as well as to report use of heroin and cocaine in combination (speedball), crack 
cocaine, powder cocaine, and heroin by itself in the last 30 days. Both unprotected 
intercourse and injection drug use in the last 30 days were more common among nonmedical 
prescription opioid users than among non-users. Although the prevalence of HCV was 
comparable across groups (18%), the prevalence of HIV infection was lower among 
nonmedical prescription opioid users (4.1%) compared with non-users (9.3%) (Table 1).
Unprotected intercourse
Characteristics of sexual encounters—A total of 1,205 participants reported on 2,006 
heterosexual encounters, of which 54% (n=1,077) were unprotected. Thirty-seven percent of 
encounters involved a study participant who was recruited from a rural county. Both partners 
were African American in 65% of the encounters and both were non-Hispanic white in 10%. 
Nonmedical prescription opioids were used by one partner in 3% of the encounters and by 
both partners in 2%. One partner binge drank in 10% of the encounters, and both partners 
binge drank in 9%. Methamphetamine was used by one partner in 1% of the encounters and 
by both partners in < 1%. Crack was used by one partner in 12% of encounters and by both 
partners in 20%. Powder cocaine was used by one partner in 10% and by both partners in 
6% of encounters. One partner used heroin in 3% of encounters and both partners used it in 
1%. In 74% of encounters, the participant reported knowing the partner for at least six 
months. Twenty-nine percent of encounters involved exchanging sex for drugs or money, 
and according to the perceptions of the participants, 4% of encounters involved HIV 
discordant partners.
Analyses of unprotected intercourse—In the univariate GEE models, individual-level 
characteristics associated with reporting unprotected intercourse included being recruited in 
a rural county, being married or living as married, being homeless, and reporting symptoms 
of depression (Table 2). At the event level, knowing a partner for at least six months, both 
partners drinking five or more alcoholic drinks, and both partners using nonmedical 
prescription opioids increased the odds of unprotected intercourse. Events that involved 
African Americans, trading sex for drugs or money, or HIV discordant partners were 
associated with decreased odds of unprotected intercourse (Table 2). In the multivariable 
analyses, general characteristics associated with increased odds of unprotected intercourse 
included: being recruited in a rural county, being married or living as married, being 
homeless, and higher depression scores. Event-level characteristics associated with 
unprotected intercourse included: knowing the partner for at least six months, both partners 
drinking five or more alcoholic drinks, and both partners using nonmedical prescription 
opioids. Events in which one partner or both partners were African American, the partners 
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were perceived to be HIV discordant, and in which sex trading occurred were associated 
with lower odds of unprotected intercourse.
Sharing high dead space syringes
Characteristics of injection episodes—A total of 192 study participants reported on 
392 injection episodes. The study participant was male in 70% of the injection episodes, 
non-Hispanic white in 30%, African American in 68%, and recruited in a rural area in 13%. 
Methamphetamine was injected in 8% of the episodes, heroin and cocaine in combination 
(speedball) in 28%, powder cocaine in 44%, heroin by itself in 28%, and prescription 
opioids in 4%. Forty percent of the episodes involved dividing liquefied drug solution, and a 
high dead space syringe was used in 25% of the episodes.
Analyses of high dead space syringe sharing—In univariate GEE models, being 
African American was the only individual-level characteristic associated with sharing a high 
dead space syringe at last injection (Table 3). Event-level characteristics associated with 
sharing a high dead space syringe at last injection included injecting nonmedical 
prescription opioids and splitting liquefied drug solution. In the multivariable model, being 
African American, injecting nonmedical prescription opioids, and splitting liquefied drug 
solution remained associated with increased odds of sharing a high dead space syringe.
Discussion
To our knowledge, this is the first paper that has examined event-level associations between 
nonmedical prescription opioid use and unprotected sex and between nonmedical 
prescription opioid use and sharing a high dead space syringe. In the event-level 
multivariable model of sexual encounters, nonmedical prescription opioid use by both 
partners was independently associated with unprotected intercourse. This model adjusted for 
potential confounders including recruitment location, HIV status, homelessness, previous 
sex with partner, and alcohol use. This suggests that nonmedical prescription opioid use 
contributes to unprotected sex in some way. This finding is consistent with findings from a 
qualitative study that found unprotected sex was common among nonmedical prescription 
opioid users (12). However, the relationship between alcohol and other drug use and risky 
sex behaviors is complex (13). In some situations, drugs may impair a person’s judgment 
and lead to him or her forgetting to use a condom (16). It is also plausible that many people 
use specific drugs with the intention of engaging in specific sexual behaviors (17). 
Accordingly, event-level associations between use of a specific drug and sex risk are 
necessary, but not sufficient, to establish a causal association.
Needle and syringe programs were, and remain, illegal in North Carolina. Pharmacies are 
the primary source of syringes for most PWID (39, 40), and almost all retail pharmacies sell 
both low dead space insulin syringes and high dead space syringes (20). The finding that 
nonmedical prescription opioid injection was independently associated with sharing a high 
dead space syringe is consistent with findings from a previous study. In that study, people 
who injected prescription opioids were more likely to use high dead space syringes than 
people who injected heroin but did not inject prescription opioids (18). Since this study was 
conducted, nonmedical prescription opioid use has increased substantially (41). This 
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increase has been linked to the growing HCV epidemic among young PWID (2). As noted 
previously, low dead space 1-ml insulin syringes may not be a viable option for nonmedical 
prescription opioid injectors who inject volumes of fluid greater than 1-ml (21).
Splitting liquefied drug solution was strongly associated with sharing a high dead space 
syringe. This is troubling because splitting liquefied drug solutions using a high dead space 
syringe may transfer many times more blood and virus than directly sharing a low dead 
space syringe (21). The association between being African American and sharing a high 
dead space syringe is consistent with findings from a previous study in Texas (42). Although 
it is not clear why African Americans are more likely to use high dead space syringes, the 
association is very concerning. The prevalence of HIV and HCV in the US is much higher 
among African Americans (43, 44), and sharing high dead space syringes could contribute to 
these disparities.
Limitations
The data for these analyses were collected from 2005 through 2008, and the prevalence and 
distribution of nonmedical prescription opioid use has likely changed since then. However, 
there is no evidence that these changes would affect the association between nonmedical 
prescription opioid use and sex risk or syringe type at the event level. The reliability and 
validity of self-reported data regarding sexual behaviors and injecting practices are 
unknown. However, we used ACASI, which has been shown to increase the validity of self-
reports of sex risk behaviors (45, 46). As with most studies of people who engage in illicit 
drug use, the representativeness of the sample is unknown. We used RDS to reduce sampling 
bias (33, 35). There were only 15 injection episodes in which prescription opioids were 
injected; therefore, the association between nonmedical prescription opioid injection and 
sharing of high dead space syringes should be interpreted cautiously. Although the event-
level questions regarding sexual encounters and injection episodes were very detailed, we 
did not include a specific question to assess why a participant did or did not use a condom. 
Neither did we ask why they injected with a specific type of syringe. Therefore, we cannot 
explain the underlying reasons for the event-level associations observed.
Conclusions
Future research on nonmedical prescription opioid use should consider its association with 
sex risk behaviors for HIV and other sexually transmitted infections. Previous studies 
suggest that nonmedical prescription opioid injection is associated with an increased risk of 
HCV infection (3). Findings from this study provide additional evidence that nonmedical 
injection of prescription opioids is associated with sharing a high dead space syringe (18). 
More research is needed to determine why African Americans are more likely to use high 
dead space syringes, including identifying structural determinants (e.g., availability of 
syringes). Additional research is needed to increase our understanding of these risk 
behaviors. However, evidence-based structural and behavioral interventions to reduce these 
risky behaviors currently exist and should be broadly implemented.
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Table 1
Characteristics of the sample by nonmedical use of prescription opioids in the last 30 days
Nonmedical prescription opioid use last 30 
days
Socio-demographic characteristics No (n=1592) Yes (n=393) Total p-value
 Mean age (SD) 40.3 (10.3) 36.0 (11.2) 39.5 (10.6) < 0.001
 % > 35 years of age 70.1 52.2 66.6 < 0.001
 % male 62.0 54.1 60.5 0.004
 % non-Hispanic white 18.7 36.9 22.3 < 0.001
 % recruited in a rural area 25.7 41.2 28.8
 % completed high school or GED 66.0 69.2 66.6 0.220
 % married or living as married 11.8 13.1 12.1 0.494
 % working full or part time 29.3 26.9 28.8 0.344
 % made $500 or more legally last 30 days 33.9 32.6 33.7 0.606
 % any type of health insurance 33.9 34.6 34.0 0.779
 % currently homeless 41.1 42.5 41.4 0.626
Incarceration and drug treatment
 % ever incarcerated 55.0 55.2 55.0 0.963
 % ever in formal drug treatment 50.7 50.4 50.6 0.921
 % currently in formal drug treatment 14.0 9.7 13.2 0.022
Alcohol and other drug use
 % drank 5 or more drinks in 2 hours last 30 days 48.3 63.9 51.4 < 0.001
 % used methamphetamine last 30 days 2.3 16.3 5.1 < 0.001
 % used heroin & cocaine in combination (speedball) last 30 days 4.7 13.0 6.4 0.001
 % used crack cocaine last 30 days 45.4 52.4 46.8 0.013
 % used powder cocaine last 30 days 27.1 57.3 33.1 < 0.001
 % used heroin by itself last 30 days 5.6 15.3 7.5 < 0.001
Sexual behavior
 % > 2 sex partners last 6 months 34.5 39.3 35.5 0.080
 % any unprotected intercourse last 30 days 42.0 54.5 44.5 < 0.001
Injecting practices
 % injected last 30 days 10.1 17.4 11.6 < 0.001
 % shared syringes last 30 days 3.2 6.1 3.8 0.006
 % ever injected 28.3 39.9 30.6 < 0.001
HIV and hepatitis C virus (HCV) test results
 % HCV positive test result 18.6 17.9 18.4 0.770
 % HIV positive test result 9.3 4.1 8.2 0.001
Psychological distress
 Mean score BSI-18 depression subscale (SD) 7.9 (5.7) 11.1 (6.7) 8.5 (6.1) < 0.001
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Table 2
Event-level analyses of unprotected vaginal or anal intercourse at last sex (sexual encounters n=2,006)
General characteristics Odds Ratio (95% CI) p-value Adjusted Odds Ratio (95% CI) p-value
 Recruited in rural county 1.78 (1.43, 2.22) < 0.001 1.57 (1.22, 2) < 0.001
 Completed high school or GED 1.01 (0.81, 1.26) 0.925
 Working full or part time 0.94 (0.75, 1.18) 0.614
 Married or living as married 1.84 (1.33, 2.54) < 0.001 1.81 (1.29, 2.54) 0.001
 Currently homeless 1.22 (0.99, 1.51) 0.061 1.65 (1.28, 2.12) < 0.001
 BSI-18 depression subscale 1.03 (1.01, 1.05) < 0.001 1.02 (1.00, 1.04) 0.026
Event-level characteristics
# African Americans in encounter
 both partners 0.44 (0.32, 0.60) < 0.001 0.62 (0.44, 0.87) 0.006
 one partner 0.42 (0.30, 0.59) < 0.001 0.56 (0.39, 0.80) 0.001
 reference category -zero partners -- -- -- --
Age of male partner 1.00 (0.99, 1.01) 0.653 1.01 (1, 1.02) 0.253
Age of female partner 1.00 (1.00, 1.01) 0.350 1 (0.99, 1.01) 0.758
Perceived HIV discordant 0.55 (0.34, 0.88) 0.012 0.55 (0.33, 0.90) 0.018
Encounter involved sex trading 0.74 (0.60, 0.91) 0.005 0.74 (0.58, 0.95) 0.020
Known partner for 6 months 1.84 (1.50, 2.26) < 0.001 1.83 (1.45, 2.30) < 0.001
5 or more alcoholic drinks
 both partners 1.69 (1.23, 2.32) 0.001 1.53 (1.07, 2.18) 0.020
 one partner 1.20 (0.89, 1.61) 0.245 1.27 (0.91, 1.77) 0.158
 Reference category-- no one used -- -- -- --
Methamphetamine
 both partners 2.51 (0.36, 17.49) 0.352 1.75 (0.37, 8.28) 0.481
 one partner 1.70 (0.82, 3.50) 0.152 1.52 (0.68, 3.40) 0.304
 Reference category-- no one used -- --
Speedball
 both partners 1.13 (0.52, 2.47) 0.755 1.75 (0.50, 6.13) 0.382
 one partner 0.50 (0.30, 0.84) 0.008 0.66 (0.35, 1.24) 0.192
 Reference category-- no one used -- -- -- --
Crack cocaine
 both partners 0.82 (0.65, 1.04) 0.107 0.87 (0.66, 1.15) 0.335
 one partner 0.86 (0.66, 1.13) 0.290 0.86 (0.63, 1.18) 0.346
 Reference category-- no one used -- --
Powder cocaine
 both partners 0.73 (0.50, 1.05) 0.091 0.60 (0.39, 0.92) 0.018
 one partner 1.19 (0.89, 1.59) 0.232 1.18 (0.85, 1.65) 0.326
 Reference category-- no one used -- -- -- --
Heroin
 both partners 0.51 (0.23, 1.17) 0.111 0.47 (0.13, 1.69) 0.247
 one partner 0.67 (0.42, 1.06) 0.085 0.71 (0.41, 1.25) 0.239
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General characteristics Odds Ratio (95% CI) p-value Adjusted Odds Ratio (95% CI) p-value
 Reference category-- no one used -- -- -- --
Non-medical prescription opioids
 both partners 2.55 (1.36, 4.79) 0.003 2.24 (1.12, 4.49) 0.023
 one partner 1.32 (0.85, 2.07) 0.220 1.09 (0.61, 1.93) 0.775
 Reference category-- no one used -- -- -- --
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Table 3
Event-level analyses of sharing a high dead space syringe at last injection (injection episodes n=392)
General characteristics OR (95% CI) p-value AOR (95% CI) p-value
Age of study participant 0.99 (0.96, 1.03) 0.743
African American 2.69 (1.08, 6.69) 0.034 3.12 (1.16, 8.38) 0.024
Non-Hispanic white 0.43 (0.17, 1.07) 0.071
Male gender (female reference category) 0.72 (0.33, 1.57) 0.413
Recruited in a rural county 1.49 (0.56, 3.93) 0.423
# of years since first injection 1.02 (0.98, 1.06) 0.305
HIV positive 0.92 (0.23, 3.63) 0.904
Event-level characteristics
Age of injection partner 1.00 (0.98, 1.01) 0.550
Ever had sex with partner 1.46 (0.87, 2.46) 0.149 1.72 (0.83, 3.56) 0.145
Injected methamphetamine 2.32 (0.87, 6.2) 0.092 2.75 (0.88, 8.64) 0.083
Injected speedball (heroin & cocaine combination) 1.19 (0.57, 2.49) 0.644
Injected powder cocaine 1.12 (0.57, 2.17) 0.743
Injected crack cocaine 2.08 (1.18, 3.69) 0.012 2.44 (1.2, 4.97) 0.014
Injected heroin 1.00 (0.43, 2.31) 0.998
Injected non-medical prescription opioids 6.25 (1.41, 27.8) 0.016 6.57 (1.63, 26.51) 0.008
Syringe-mediated drug sharing (split liquefied drug solution) 7.77 (3.56, 17) < 0.001 7.95 (3.32, 19.02) < 0.001
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